Diurnal (DNL)

Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions.

They are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).

Diurnal’s expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body’s natural hormone levels), which has yielded novel product candidates being trialled in patients prior to the submission of a marketing authorisation application.

NetScientific (NSCI)

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

NetScientific funds, develops, and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

Scotgold Resources (SGZ)

Scotgold Resources (SGZ) is a mineral exploration company that offers opportunities to investors in the increasingly attractive gold mining industry through the development of the Cononish Mine in Scotland.

ThinCats

ThinCats is one of the pioneers of the peer-to-peer business lending industry; specialising in loans with security and linking retail and institutional investors directly with established business borrowers to provide an alternative to high street banks.

The company was founded in the aftermath of the global financial crisis, with the aim of offering loans to UK businesses struggling to access funding through traditional channels, whilst providing investors with attractive rates of interest unavailable through many conventional investment portfolios.

A key element of the ThinCats ethos has always been to avoid the algorithm-led decision making often used by banks; the founders were keen to hear the stories behind the borrowers’ investment needs, and assess each one based on its merits. The company continues to work in this way, harnessing the knowledge of financial experts to assess each loan application, thereby encouraging growth, development and innovation in UK business.

ValiRx (VAL)

ValiRx Plc (VAL) is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering.